antileukinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	9876474
SCHEMBL ID	22597782
MeSH ID	M0304752

Synonyms (8)

Synonym
antileukinate
138559-60-1
AKOS027250749
(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diamino
ac-arg-arg-trp-trp-cys-arg-nh2
SCHEMBL22597782
CS-0092315
HY-125567

Research Excerpts

Treatment

Antileukinate protected mice against acute pancreatitis and associated lung injury. Anti-chemokine therapy may be of value in this condition.

Excerpt	Reference	Relevance
"Antileukinate-treated Tg mice had significantly decreased pulmonary inflammation and oxidative stress compared to Antileukinate-treated WT mice (p < 0.05) or Antileukinate-non-treated Tg mice (p < 0.05)."	( Synergistic protection against hyperoxia-induced lung injury by neutrophils blockade and EC-SOD overexpression. Ahmed, MN; Codipilly, CN; Miller, EJ; Min, JH; Nasim, S, 2012)	1.82
"Treatment with antileukinate protected mice against acute pancreatitis and associated lung injury, showing thereby that anti-chemokine therapy may be of value in this condition."	( Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Bhatia, M; Hegde, A, 2007)	1.03

Dosage Studied

Excerpt	Relevance	Reference
" Because the role of activated neutrophils in the development of allograft rejection is believed to be biphasic, we used specific CXC receptor inhibition with antileukinate in 2 dosing regimens."	( Prevention of neutrophil migration ameliorates rat lung allograft rejection. Higuchi, T; Hirayama, S; Miller, EJ; Shiraishi, T; Shirakusa, T, )	0.33

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (10.00)	18.2507
2000's	7 (70.00)	29.6817
2010's	2 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.98 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.47 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.98)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (9.09%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	7.01	1
sb 225002 [no description available]	3.1	1	nitrophenol
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.03	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.4	2

Condition	Relationship Strength	Studies
Infections, Listeria [description not available]	2.07	1
Hyperoxia An abnormal increase in the amount of oxygen in the tissues and organs.	2.07	1
Chronic Lung Injury [description not available]	2.07	1
Acute Respiratory Distress Syndrome [description not available]	2.71	3
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	2.71	3
Eosinophilia, Tropical [description not available]	2.01	1
Innate Inflammatory Response [description not available]	2.42	2
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	2.01	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.42	2
Blood Poisoning [description not available]	2.42	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.02	1
Bleeding [description not available]	2.02	1
Hemorrhage Bleeding or escape of blood from a vessel.	2.02	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.42	2
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.02	1
Pneumonia Infection of the lung often accompanied by inflammation.	2.02	1
Disease, Pulmonary [description not available]	2.03	1
Acute Edematous Pancreatitis [description not available]	2.03	1
Lung Diseases Pathological processes involving any part of the LUNG.	2.03	1
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	7.03	1
Adenocarcinoma, Basal Cell [description not available]	2	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2	1

chemdatabank.com